Deep Liver Phenotyping and Immunology Study (DELPHI)

• ClinicalTrials.gov Identifier: NCT04946773
• Recruitment Status: Recruiting
• First Posted: July 1, 2021
• Last Update Posted: April 6, 2022
• Sponsor: University of Oxford
• Information provided by (Responsible Party): University of Oxford

Tracking Information

• First Submitted Date: June 9, 2021
• First Posted Date: July 1, 2021
• Last Update Posted Date: April 6, 2022
• Actual Study Start Date: March 12, 2021
• Estimated Primary Completion Date: October 31, 2040 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 28, 2022)

Measurement of intra-hepatic and peripheral blood immune cell numbers in Malignancy Cohort and Control Cohort patients. [ Time Frame: At study enrolment ]

Proportion of immune cell populations relative to total immune cell count measured by single cell RNA sequencing.

Original Primary Outcome Measures (submitted: June 22, 2021)

Defining the differences in the hepatic immune microenvironment that are associated with malignancy. [ Time Frame: At study enrolment ]

Between group comparison of intra-hepatic and peripheral immune cell populations determined by single cell RNA sequencing.

Current Secondary Outcome Measures (submitted: March 28, 2022)

Measurement of liver cancer occurrence and all-cause mortality. [ Time Frame: 15 years ]

Measurement of absolute numbers of liver cancers and deaths in study patients

Original Secondary Outcome Measures (submitted: June 22, 2021)

• Long-term follow-up of patient cohorts [ Time Frame: 15 years ]
  Passive data collection on occurrence or recurrence of hepatic & hepatobiliary malignancy
• Identify candidate biomarkers [ Time Frame: 15 years ]
  Biomarkers for for early detection or early diagnosis of hepatic & hepatobiliary malignancy

Current Other Pre-specified Outcome Measures (submitted: March 28, 2022)

• Measure safety of fine needle aspiration in cirrhosis [ Time Frame: 5 years ]
  Measurement of absolute numbers of adverse events related to liver fine needle aspiration in study patients with cirrhosis.
• Measure tolerability of liver fine needle aspiration [ Time Frame: 5 years ]
  Measure post procedure analgesia dose and duration in patients undergoing liver fine needle aspiration as a study procedure

Original Other Pre-specified Outcome Measures (submitted: June 22, 2021)

• Fine needle aspiration in cirrhosis: safety [ Time Frame: 5 years ]
  Monitoring the safety of liver fine needle aspiration as a research procedure in cirrhotic patient cohorts. Determined through documentation of adverse events.
• Fine needle aspiration in cirrhosis: Tolerability [ Time Frame: 5 years ]
  Monitoring the tolerability of liver fine needle aspiration as a research procedure in cirrhotic patient cohorts. Evaluation of subjective post-procedure pain scores.

Descriptive Information

• Brief Title: Deep Liver Phenotyping and Immunology Study
• Official Title: Deep Liver Phenotyping and Immunology Study

Brief Summary

Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide. It is known that most of these cancers occur in patients who already have a liver condition. Despite close monitoring of many patients who have liver disease with regular ultrasound scans, HCC and cholangiocarcinoma are often discovered at a late stage. This is because they rarely cause symptoms until they have reached an advanced stage. Early identification of these cancers would enable more patients to have curative treatments such as surgery or liver transplantation.

The investigators want to collect blood and urine samples as well as small samples of cells directly from the liver. In some cases this will be done using a technique called liver fine needle aspiration. This technique is low risk and has been successfully used in other studies. The investigators will compare samples from patients with cancer to those of patients with other diseases of the liver who are at risk of developing cancer in the future.

The investigators aim to detect changes in the liver, blood, urine and/or bile of patients who have liver conditions that could tell us their risk of a future cancer. These changes could be in the types of white blood cells found within the liver, or, they may be in products secreted by liver cells. In the latter case the liver cells may release small pieces of their DNA that could be detected in the blood. When liver cells are dysfunctional, they may also change the types of metabolic products that they produce, and the investigators may be able to detect these changes in the urine or bile.

Detailed Description

The purpose of this study is to perform a characterisation of the cancer predisposing 'field effect' that is associated with hepatic & hepato-biliary malignancy, and, to identify minimally invasive biomarkers that may detect this field effect. This will be achieved through collection of patient samples (Tissue/Blood/Urine/Bile). Comparisons will then be made between patients with hepatic & hepatobiliary cancer and patients with chronic liver disease and also longitudinally in individual patients who either develop or are cured of hepatic & hepato-biliary malignancy during the study. The investigators hope to exploit this knowledge to develop novel biomarker candidates that may ultimately form inputs to a multi-parametric early cancer detection model. The study aims are:

1. Develop a cohort of patients with HCC, cholangiocarcinoma or liver metastases and a cohort of chronic liver disease patients representing all the commonly encountered aetiologies (viral, metabolic, autoimmune and alcohol related liver disease).
2. Collect samples from directly within the non-cancerous liver (FNA liver/biopsy/ablation/resection specimens), blood and urine in addition tumour tissue (resection/biopsy/ablation), bile and bile duct brushings.
3. Flow cytometric & molecular biologic analysis of tissue and peripheral blood and bile.
4. Transcriptomic analysis of cell populations in liver and blood.
5. Genetic & molecular biologic analysis of hepatic and immune cells and secreted products.

• Study Type: Observational [Patient Registry]
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: 15 Years

Biospecimen

Retention:   Samples With DNA

Description:

Tissue, blood, urine & bile

• Sampling Method: Non-Probability Sample
• Study Population: Hepatology patients treated at a single hospital trust.

Condition

• Hepatocellular Carcinoma
• Cholangiocarcinoma

• Intervention: Not Provided

Study Groups/Cohorts

• Malignancy Cohort
  Patients with hepatic or hepatobiliary malignancy at enrolment
• Control Cohort
  Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: June 22, 2021): 100
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: October 31, 2040
• Estimated Primary Completion Date: October 31, 2040 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in the study.
• Male or Female, aged 18 years to 75 years.

Malignancy Cohort: extra inclusion criteria - Diagnosed with a malignancy or with clinical suspicion of a malignancy affecting the Liver or Biliary Tree.

Control cohort: extra inclusion criteria

- Patients with confirmed chronic non-malignant hepatobiliary disease.

Additional Inclusion Criteria for Patients Undergoing optional Liver FNA

• Willing to undergo ultrasound guided liver FNA (unless specific contra-indications to the procedure apply).
• Has undergone appropriate clinical imaging of the upper abdomen (US/CT/MRI) within the last 12 months.
• Full blood count (FBC) and coagulation profile (Coag) checked within 30 days prior to FNA procedure (Baseline Visit).

Exclusion Criteria:

• Unable to consent.
• Pregnancy.
• Any concern by the investigator regarding the safe participation of the patient in the study; or investigator's consideration, for any other reason, that a patient is inappropriate for participation in the study.

Additional Exclusion Criteria for Patients Undergoing optional Liver FNA (These criteria will exclude a patient from having FNA as part of the study)

• Significant comorbid medical condition(s) which may in the opinion of the investigator increase the risk of an FNA Liver.
• Coagulopathy - International Normalized Ratio (INR) >1.3, Prothrombin Time (PT) >16 seconds, Platelet count <100 x 10^3/L.
• Known bleeding disorder (e.g. Haemophilia).
• Current use of an oral/injectable anticoagulant medication.
• Current use of an oral antiplatelet agent.
• The presence of ascites.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Rory J Peters; +441865220077; Rory.peters@ndm.ox.ac.uk

• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT04946773
• Other Study ID Numbers: 264839; C2195/A27431 ( Other Grant/Funding Number: Cancer Research UK ); CA30358/A29725 ( Other Grant/Funding Number: Cancer Research UK )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: University of Oxford
• Original Responsible Party: Same as current
• Current Study Sponsor: University of Oxford
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Rory J Peters; University of Oxford

• PRS Account: University of Oxford
• Verification Date: March 2022